ABSTRACT BACKGROUND Higher androgen and lower estrogen levels are associated with cardiovascular disease (CVD) risk fac-
A therosclerotic cardiovascular disease (CVD), which includes coronary heart disease (CHD) and ischemic stroke, affects men and women differently. In women, the risk of CVD is much lower than in men until 50 years of age, but it rises dramatically after menopause (1) . It has been hypothesized that lower levels of endogenous estrogens and higher endogenous androgens that occur as a consequence of the menopausal transition might mediate the increased CVD risk later in life in post-menopausal women (1, 2) . This theory has been supported by observational studies that demonstrate associations between higher androgen and lower estrogen levels with CVD risk factors in post-menopausal women, including elevated blood pressure, C-reactive protein (CRP), and insulin resistance (1, (3) (4) (5) .
Studies examining the associations between sex hormone levels and CVD events in post-menopausal women, however, have yielded conflicting results. Both high (6,7) and low (8, 9) androgen levels have been associated with increased risk of CVD. With respect to estrogens, observational studies have demonstrated that estradiol levels in women were either not associated (7, 10) or inversely associated with CVD events (6) .
As a result, the relationship of sex hormones with CVD events in post-menopausal women is still unclear.
Studies of the association between sex hormone levels and clinical CVD events in post-menopausal women, however, have been limited by suboptimal measurement of CVD events (10) , use of hospitalbased study populations (9, 11) , small sample size (11) , or short duration of follow-up (7) . Therefore, we used data from the MESA (Multi-Ethnic Study of Atherosclerosis) to evaluate the association of sex hormone levels with incident CVD, CHD, and heart failure (HF) events over 12-year follow-up in a community-based population of post-menopausal women free of CVD at baseline. Total testosterone and dehydroepiandrosterone (DHEA) were measured using radioimmunoassay kits.
Sex hormone binding globulin (SHBG) was measured using a chemiluminescent enzyme immunometric assay (Immulite kits, Diagnostic Products Corporation, Los Angeles, California). Estradiol was measured using an ultrasensitive radioimmunoassay kit (Diagnostic System Laboratories, Webster, Texas). Concentrations of bioavailable testosterone (the sum of SHBG-bound and albumin-bound testosterone) and free testosterone (reported as a percentage of total testosterone)
were calculated according to the method of Södergård (13) . We divided total testosterone by estradiol to calculate total testosterone/estradiol ratio for each participant. Quality control serum was obtained from an w10% blind pool. The coefficients of variation for total testosterone, SHBG, DHEA, and estradiol were 12.3%, 9.0%, 11.2%, and 10.5%, respectively (4). The associations between CVD risk factors and sex hormone levels were evaluated using multivariableadjusted linear regression with log e -transformed sex hormone levels as dependent variables. The study endpoints were the development of incident CVD, CHD, or HF. Participants were followed from the Values are mean AE SD, median (interquartile range), or n (%). To convert total, HDL, and LDL cholesterol from mg/dl to mmol/l, divide by 38.67. To convert total testosterone, free testosterone, bioavailable testosterone DHEA from nmol/l to ng/dl, divide by 0.0347. To convert estradiol from nmol/l to ng/ml, divide by 3.67. To convert SHBG from nmol/l to mg/l, divide by 10.5263.
BMI ¼ body mass index; BP ¼ blood pressure; CRP ¼ C-reactive protein; CVD ¼ cardiovascular disease; DHEA ¼ dehydroepiandrosterone; eGFR ¼ estimated glomerular filtration rate; HDL ¼ high-density lipoprotein; IL ¼ interleukin; LDL ¼ low-density lipoprotein; MESA ¼ Multi-Ethnic Study of Atherosclerosis; MET-min ¼ metabolic equivalent task-minute; SHBG ¼ sex hormone binding globulin; T ¼ testosterone.
antihypertensive medications, total cholesterol, high-density lipoprotein cholesterol, use of lipid lowering medication, diabetes, eGFR, CRP, IL-6, fibrinogen, and D-dimer. In the primary analyses, the associations between sex hormones and each of the CVD endpoints were modeled separately for each individual hormone. In secondary analyses, we included total testosterone, estradiol, DHEA, and All sex-hormones are log-transformed and standardized. Hazard ratios are associated with 1-SD increase in log sex hormones. Bold results are statistically significant. Model 1 adjusts for age (year, continuous), race/ethnicity (white, black, Hispanic, and Chinese), study site (California, Minnesota, New York, Illinois, North Carolina, and Maryland), and use of hormone therapy (yes, no). Model 2 adjusts for model 1 variables þ education (<high school, high school, >high school), waist-to-hip ratio (continuous), physical activity, and smoking (never, former, current). Model 3 adjusts for model 2 variables þ systolic blood pressure (mm Hg, continuous), use of antihypertensive medications (yes, no), total cholesterol (mg/dl, continuous), HDL cholesterol (mg/dl, continuous), use of lipid-lowering medications (yes, no), diabetes (yes, no), eGFR (ml/min/1.73 m 2 ), CRP (mg/l, logtransformed continuous), IL-6 (pg/ml, log-transformed, continuous), fibrinogen (mg/dl, log-transformed continuous), D-dimer (mg/ml, log-transformed continuous).
CHD ¼ coronary heart disease; CI ¼ confidence interval; HF ¼ heart failure; HR ¼ hazard ratio; IR ¼ incidence rate; other abbreviations as in Table 1 .
SHBG in the fully adjusted model to mutually account for one another.
We performed stratified analyses in pre-specified subgroups defined by age and race/ethnicity. We also performed sensitivity analyses excluding women who were using HT at baseline (because estradiol levels differ substantially among women taking vs. not taking HT), and using hard CVD and hard CHD events as endpoints instead of all CVD and CHD events.
Additionally, we conducted analysis using non-CVD death as a competing risk. All reported p values were 2-sided, and the significance level was set at 0.05.
Statistical analyses were performed using STATA version 14 (StataCorp LP, College Station, Texas).
RESULTS
The baseline characteristics of the study population are presented in Table 2 ) (model 3).
Estradiol levels were not associated with overall CVD events, but were associated with a lower risk for CHD, with a non-significant trend for lower HF risk.
The fully adjusted HRs for CVD, CHD, and HF asso- Regarding the HF subtypes, testosterone/estradiol ratio was positively associated, and both estradiol , CRP (mg/l, log-transformed continuous), IL-6 (pg/ml, log-transformed, continuous), fibrinogen (mg/dl, log-transformed continuous), D-dimer (mg/ ml, log-transformed continuous).
HT ¼ hormone therapy; other abbreviations as in Tables 1 and 2. and DHEA inversely associated, with HFrEF, but not HFpEF ( Table 2 In sensitivity analyses excluding women taking HT (Table 3) , testosterone/estradiol ratio remained Total T Distribution (%)
The curves represent the adjusted HR of CVD/CHD/HF by log sex hormone levels. The dose response association was estimated by using a linear and a cubic spline term for each sex hormone in the multivariable cox regression. Curves represent adjusted HR (solid line) and 95% confidence interval (dashed lines) based on restricted cubic splines for sex hormones with knots at the 5th, 35th, 65th, and 95th percentiles of their sample distributions. The reference values (diamonds) were set at the 10th percentile. The model was adjusted for age, race/ethnicity, study center, education, waist-to-hip ratio, physical activity, smoking, systolic blood pressure, use of antihypertensive medications, total cholesterol, high-density lipoprotein cholesterol, use of lipid-lowering medications, diabetes, estimated glomerular filtration rate, use of hormone therapy, log(C-reactive protein), log(interleukin-6), log(fibrinogen), and log(D-dimer). (A) Total testosterone (T) (nmol/l); (B) estradiol (nmol/l); and (C) testosterone/estradiol ratio. CHD ¼ coronary heart disease; CVD ¼ cardiovascular disease; E ¼ estradiol; HF ¼ heart failure; HR ¼ hazard ratio; T ¼ testosterone. Table 3 for all women and
Online Table 4 for women not on HT). Additional competing risk analyses yielded similar results to primary analysis (Online Table 5 ).
In spline regression analyses, the risk of incident CVD and CHD increased progressively with total testosterone levels and testosterone/estradiol ratio (Figures 2A and 2C) , and the risk of incident CHD and HF decreased progressively with estradiol levels The associations between sex hormones and CVD outcomes were generally consistent across all age and race/ethnic subgroups, except that in younger participants (<65 years of age), the association of DHEA levels with CVD, CHD, and HF endpoints was inverse whereas it was null in older participants ($65 years) ( Figure 3) . Zhao et al.
DISCUSSION
Among racially/ethnically diverse post-menopausal women followed for >12 years, we found that higher testosterone/estradiol ratio was associated with an elevated risk for incident CVD, CHD, and HF events, higher total testosterone was associated with increased risk of CVD and CHD, and higher estradiol levels were associated with a lower risk of (A) Boxplot distribution of the testosterone/estradiol ratio by outcome status (unadjusted). The bottom and top of the box are the first and third quartiles, and the band inside the box is the second quartile (the median). The whiskers represent the first quartile -1.5Â interquartile range and 3rd quartile þ1.5Â interquartile range.
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(B) Adjusted hazard ratio of CVD/CHD/HF for testosterone/estradiol ratio using restricted cubic spline with knots at the 5th, 35th, 65th, and 95th percentiles of the sample distribution. The reference value (diamond) was set at the 10th percentile. The model was adjusted for age, race/ethnicity, study center, use of hormone therapy, education, waist-to-hip ratio, physical activity, smoking, systolic blood pressure, use of antihypertensive medications, total cholesterol, high-density lipoprotein cholesterol, use of lipid lowering medications, diabetes, estimated glomerular filtration rate, log(C-reactive protein), log(interleukin-6), log(fibrinogen), and log(D-dimer). CHD ¼ coronary heart disease; CVD ¼ cardiovascular disease; HF ¼ heart failure; MESA ¼ Multi-Ethnic Study of Atherosclerosis.
function and modulating autonomic function. Additionally, estrogen is thought to regulate specific inflammatory markers and cytokines (19) . By contrast, testosterone can induce vasoconstriction and increased platelet aggregation through up-regulation of thromboxane (20) . In population studies, androgens are associated with increased accumulation of visceral fat, lipid levels, and increased levels of cardiometabolic risk factors (2, 3, 21) , including blood pressure, body mass index, CRP, and insulin resistance in women (1, (3) (4) (5) . Furthermore, a history of early age of menopausal onset and shorter duration from menarche to menopause are associated with higher risk of cardiovascular outcomes, including CVD mortality, CHD, and HF (22, 23) ; this again suggests a role of sex hormones in disease pathogenesis. years of follow-up had a higher baseline free androgen index compared with controls, but the association was null after adjustment for CVD risk factors (7) , and a population-based cohort study in Germany (N ¼ 2,129 middle-aged women, 11-year follow-up) also concluded that baseline total testosterone was not associated with incident CVD or mortality (24) . Furthermore, the Rancho Bernardo Study (8, 10) (N ¼ 639 post-menopausal women, 12-year follow-up) and a hospital-based cohort study in Germany (9) (N ¼ 2,914 women between 18 and 75 years of age, 4.5-year follow-up) both found that lower baseline levels of total testosterone were associated with increased CVD events, which contrasts with our findings.
With respect to estrogens, a population-based study in Denmark found that lower estradiol levels were associated with increased risk of CHD and death (6) , but the WHS trial (7), Rancho Bernardo Study (8, 10) , and a nested case-control study of elderly diabetic women (11) found no association between estradiol levels and CVD events.
Several methodological differences could explain the discrepancies in the associations observed in previous studies. First, previous studies have used different study designs, with a mixture of cohort (8, 9, 24) , nested cohort (6), nested case-control designs (7), with follow-up times ranging from 4 to almost 30 years. Second, the study populations were very diverse, with mean age ranging from 49 to 74 years. Finally, these studies used different measurements of CVD events, including self-reports (8, 10, 24) , national patient registries (6) , and medical records (7, 9) .
Our study supports an association of higher total testosterone levels and higher testosterone/estradiol ratio with increased CVD and CHD events in postmenopausal women, as well as an association of higher estradiol levels with reduced CHD and HF events, although the association between estradiol and HF did not reach statistical significance (HF events were fewer than CHD events, with therefore less power to detect associations). Among HF subtypes, we found that higher testosterone/estradiol ratio and lower estradiol levels were associated with increased risk for HFrEF, but not HFpEF, the type of HF more commonly seen in older women. It is possible that the reduction in estradiol during menopause differentially affects vascular and cardiac remodeling processes that differentially lead to a HFrEF versus HFpEF phenotype. Lower levels of estradiol are associated with risk for hypertension (25) , a risk factor for HFrEF. In our study, estradiol was associated with CHD, and CHD may contribute more to HFrEF than to HFpEF. As mentioned, our results contradicted the 2 Germany studies and Rancho Bernardo Study that showed null or reversed association between total testosterone and CVD events (8, 9, 24) . The difference may be due to the selection of study participants (younger women with mean age 49 years, and hospital-based in the German study) or ascertainment of CVD outcome (self-report in Rancho Bernardo Study). Further studies are needed to confirm these findings and to better understand the associations and mechanisms between sex hormones and subtypes of HF.
In our study, SHBG and DHEA levels were not associated with CVD, CHD, or overall HF. However, SHBG was associated with increased risk for CHD in women not taking HT. This result aligns with a previous MESA study analysis showing that SHBG was positively associated with coronary artery calcification (15) . Nevertheless, other studies have not found an association between SHBG and incident CVD (7, 10, 11, 24) . Additionally, in our study, DHEA was inversely associated with HFrEF risk, an association that needs to be confirmed in other studies. The role of DHEA on CVD is still undefined. It was hypothesized that lower DHEA levels might be related to increased risk of CVD (26) , but this association was refuted by many studies, especially among women (27, 28) .
Although sex hormone levels may be linked to future CVD events, it is unclear what the best However, our results should be considered in the context of some limitations. First, despite the sample size and the long duration of follow-up, the number of events observed in our study was limited for some outcomes, particularly for HF subtypes and ischemic stroke, limiting our power to detect associations. Additionally, although large variation of associations across race/ethnicity were seen, the sample size may limit the detection of significant interaction between sex hormone levels and race/ ethnicity. Second, we studied multiple sex hormones and outcomes, and some associations may have been observed by chance. However, we based our conclusions not only on significance tests, but also on biological plausibility, dose-response, and consistency of the associations. Third, although we adjusted for multiple potential confounders, we cannot exclude the possibility of residual confounding. Fourth, menopausal status was self-reported and subject to reporting bias, although we corrected self-reported menopausal status using an algorithm based on age, self-reported hysterectomy, bilateral oophorectomy, and menopausal age. Finally, sex hormone levels were only assessed once at baseline and were not repeatedly measured during follow-up. In particular, we did not have information on sex hormone levels before and during the menopausal transition. As a consequence, we could not examine the association of changes in sex hormone levels with CVD events.
CONCLUSIONS
Our study suggests that, in post-menopausal women, higher testosterone/estradiol ratio is associated with the development of CVD, CHD, and HF events, whereas estradiol is associated with a reduced risk of CHD and HFrEF. Sex hormone levels, especially higher total testosterone versus estrogen after menopause, may contribute to women's increased CVD risk later in life. However, in the absence of supportive interventional studies, the best strategy to modify sex hormone levels to affect CVD risk is still uncertain. Nonetheless, a more androgenic sex hormone profile may identify a woman at higher risk for CVD who may benefit from other risk-reducing strategies. KEY WORDS cardiovascular disease, coronary heart disease, estradiol, heart failure, sex hormone binding globulin, sex hormones, testosterone APPENDIX For supplemental tables, please see the online version of this paper.
